Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

• Published in: Diabetologia Vol. 52; no. 1; pp. 17 - 30
• Main Authors: Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.01.2009; Springer; Springer Nature B.V
• Subjects: Algorithms; Biological and medical sciences; Consensus Statement Update; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - psychology; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Europe; Human Physiology; Hyperglycemia - drug therapy; Hyperglycemia - prevention & control; Hyperglycemia - psychology; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Internal Medicine; Life Style; Medical sciences; Medicine; Medicine & Public Health; Metabolic Diseases; Societies, Medical; United States; United States; Europe; HbA1c Level; Glycaemic Control; Lifestyle Intervention; Consensus Algorithm; Metformin; Endocrinopathy; Type 2 diabetes; Metabolic diseases; Hyperglycemia; Association
• ISSN: 0012-186X; 1432-0428; 1432-0428
• DOI: 10.1007/s00125-008-1157-y

The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new interventions and new evidence to establish their clinical role. The authors continue to endorse the principles used to develop the algorithm and its major features. We are sensitive to the risks of changing the algorithm cavalierly or too frequently, without compelling new information. An update to the consensus algorithm published in January 2008 specifically addressed safety issues surrounding the thiazolidinediones. In this revision, we focus on the new classes of medications that now have more clinical data and experience.